TWi Biotechnology

TWi Biotechnology completes phase II trial patient enrollment

Monday, June 24, 2013

TWi Biotechnology has completed patient enrollment in a phase II trial of AC-201 for Gout Flare Prophylaxis (GFP) during urate-lowering therapy (ULT). This randomized, double-blind, placebo-controlled phase II study is conducted in eight medical centers in Taiwan and includes patients with acute arthritis of primary gout and elevated serum uric acid. A total of 82 patients were randomized at a 1:1 ratio to receive 50mg AC-201 or placebo twice daily in addition to the ULT during the 16-week treatment period.

[Read More]